(57 days)
Not Found
No
The device description and performance studies focus on the physical properties and clinical safety of a contact lens, with no mention of AI or ML technology.
No.
The device is indicated for the correction of refractive ametropia (myopia, hyperopia, and astigmatism), which is a corrective function, not a therapeutic one.
No
This device is a contact lens intended for the correction of refractive ametropia (myopia, hyperopia, and astigmatism), which is a treatment rather than a diagnostic function.
No
The device description clearly indicates it is a physical contact lens made of a copolymer, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The SofLens® daily disposable contact lens is a medical device intended to be placed on the surface of the eye to correct refractive errors (myopia, hyperopia, astigmatism). It does not analyze samples from the body.
- Intended Use: The intended use clearly states the correction of refractive ametropia, which is a physical correction of vision, not a diagnostic test.
- Device Description: The description details the physical properties and composition of the lens itself, not reagents or equipment used for analyzing biological samples.
Therefore, the SofLens® daily disposable contact lens falls under the category of a medical device, specifically a contact lens, and not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is indicated for the daily wear correction of refractive ametropia (myopia, hyperopia and astigmatism) in aphakic and/or not-aphakic persons with nondiseased eyes, that exhibit refractive astigmatism up to 2.00 diopters or less, that does not interfere with visual acuity. The lens may be prescribed in spherical powers ranging from +20.00D to -20.00D.
The lens is to be prescribed for single-use disposable wear, and is to be discarded after each removal.
Product codes (comma separated list FDA assigned to the subject device)
MVN
Device Description
The SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is a hemispherical flexible shell which covers the cornea and may cover a portion of the adjacent sclera. It consists of a copolymer of 2-hydroxyethyl methacrylate and N-vinyl pyrrolidone, and is 59% water by weight when immersed in a sterile saline solution. This lens is tinted blue with Reactive Blue Dye 246 ((1,4-Bis[4-(2-methacryloxyethyl) phenylamino] anthraquinone). The color additive conforms with 21 CFR Part 73.3106. The lens may also be supplied clear (no tint).
The physical / optical properties of the lens are:
Specific Gravity: 1.119
Refractive Index: 1.4036
Light Transmittance: C.I.E. Y value - at least 97%
Water Content: 59%
Oxygen Permeability (Dk): 22 x10^-11 [cm³O₂(STP) x cm]/(sec x cm² x mmHg)@35°C (Polarographic Method)
The SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is a hemispherical shell of the following dimensions:
Diameter: 13.5mm to 15.0mm
Center Thickness: 0.05mm to 0.75mm
Base Curve: 7.8mm to 9.5mm
Powers (Spherical): +20.00D to -20.00D
Each SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is supplied in a plastic blister container with a saline solution. The container is marked with the manufacturing lot number of the diameter, sphere power, base curve and expiration date.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
nondiseased eyes
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A series of preclinical and clinical studies have been completed and were previously submitted under submissions K994125 and K974780.
Non-Clinical Laboratory Testing: A series of in vitro and in vivo preclinical toxicology and biocompatibility testing was performed to assess the safety and effectiveness of the contact lens. Testing was performed in accordance with FDA guideline titled Premarket Notification (510(k)) Guidance Document for Daily Wear Contact Lenses. May 1994. The non-clinical testing can be found in the currently marketed SofLens®59 (hilafilcon B) Visibility Tinted Contact Lens 510(k) Premarket Notification K994125 cleared on March 3, 2000.
Stability testing has demonstrated a five year expiration date for the sterile lenses.
Clinical Testing: There is no change in the lens material, the manufacturing process, nor the parameters and properties, therefore, the clinical data previously submitted in K994125 and K974780 supports the clinical safety and effectiveness of the subject device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 886.5925 Soft (hydrophilic) contact lens.
(a)
Identification. A soft (hydrophilic) contact lens is a device intended to be worn directly against the cornea and adjacent limbal and scleral areas of the eye to correct vision conditions or act as a therapeutic bandage. The device is made of various polymer materials the main polymer molecules of which absorb or attract a certain volume (percentage) of water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.
0
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens
1. Submitter Information:
Bausch & Lomb Incorporated 1400 North Goodman Street Rochester, NY 14603
| Contact Person: | Debra Ketchum
Manager, Regulatory Affairs |
|-----------------|----------------------------------------------|
| Telephone No.: | (585) 338-8638 |
2. Device Name:
Classification Name: Soft (hydrophilic) contact lens
Proprietary Name: SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens
3. Predicate Devices:
SofLens® one day disposable (hilafilcon A) Visibility Tinted Contact Lens (K974780 and K011718)
SofLens®59 (hilafilcon B) Visibility Tinted Contact Lens (K994125)
1
4. DESCRIPTION OF DEVICE
The SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is a hemispherical flexible shell which covers the cornea and may cover a portion of the adjacent sclera. It consists of a copolymer of 2-hydroxyethyl methacrylate and N-vinyl pyrrolidone, and is 59% water by weight when immersed in a sterile saline solution. This lens is tinted blue with Reactive Blue Dye 246 ((1,4-Bis[4-(2-methacryloxyethyl) phenylamino] anthraquinone). The color additive conforms with 21 CFR Part 73.3106. The lens may also be supplied clear (no tint).
The physical / optical properties of the lens are:
| Specific Gravity: | 1.119 |
|---|---|
| Refractive Index: | 1.4036 |
| Light Transmittance: | C.I.E. Y value - at least 97% |
| Water Content: | 59% |
| Oxygen Permeability (Dk): | 22 x10-11[cm³O₂(STP) x cm]/(sec x cm² x mmHg)@35°C |
| (Polarographic Method) |
The SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is a hemispherical shell of the following dimensions:
| • Diameter: | 13.5mm to 15.0mm |
|---|---|
| • Center Thickness: | 0.05mm to 0.75mm |
| • Base Curve: | 7.8mm to 9.5mm |
| • Powers (Spherical): | +20.00D to -20.00D |
Each SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is supplied in a plastic blister container with a saline solution. The container is marked with the manufacturing lot number of the diameter, sphere power, base curve and expiration date.
2
5. INDICATIONS FOR USE
The SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is indicated for the daily wear correction of refractive ametropia (myopia, hyperopia and astigmatism) in aphakic and/or not-aphakic persons with nondiseased eyes, that exhibit refractive astigmatism up to 2.00 diopters, that does not interfere with visual acuity. The lens may be prescribed in spherical powers ranging from +20.00D to -20.00D.
The lens is to be prescribed for single-use disposable wear and is to be discarded after each removal.
DESCRIPTION OF SAFETY AND SUBSTANTIAL EQUIVALENCE 6.
A series of preclinical and clinical studies have been completed and were previously submitted under submissions K994125 and K974780.
Non-Clinical Laboratory Testing:
A series of in vitro and in vivo preclinical toxicology and biocompatibility testing was performed to assess the safety and effectiveness of the contact lens. Testing was performed in accordance with FDA guideline titled Premarket Notification (510(k)) Guidance Document for Daily Wear Contact Lenses. May 1994. The non-clinical testing can be found in the currently marketed SofLens®59 (hilafilcon B) Visibility Tinted Contact Lens 510(k) Premarket Notification K994125 cleared on March 3, 2000.
Stability testing has demonstrated a five year expiration date for the sterile lenses.
Clinical Testing:
There is no change in the lens material, the manufacturing process, nor the parameters and properties, therefore, the clinical data previously submitted in K994125 and K974780 supports the clinical safety and effectiveness of the subject device.
Substantial Equivalence
The SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is similar to the SofLens one day disposable (hilafilcon A) and SofLens®59 (hilafilcon B) Visibility Tinted Contact Lenses in that all three lenses fall into FDA Group II for soft (hydrophilic) contact lenses because the ionic content is less than 1% (nonionic polymer material), and the water content is greater than 50% (59% and 70% water) and are manufactured with the same manufacturing process (cast molding). The SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is different from the SofLens® one day disposable (hilafilcon A) Visibility Tinted Contact Lens in that the lens material has a different USAN name suffix (hilafilcon A vs. hilafilcon B),
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is an abstract symbol that resembles a stylized caduceus, a traditional symbol of medicine, with a staff and intertwined snakes.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUN 2 2 2006
Bausch & Lomb, Inc. c/o Ms. Debra Ketchum Manager, Regulatory Affairs 1400 N. Goodman Street Rochester, NY 14609
Re: K061157
Trade/Device Name: Bausch & Lomb SofLens® Daily Disposable (hilafilcon B) Visibility Tinted Contact Lens Regulation Number: 21 CFR 886.5925 Regulation Name: Soft (hydrophilic) contact lens Regulatory Class; Class II Product Code: MVN Dated: June 8, 2006 Received: June 9, 2006
Dear Ms. Ketchum:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
4
Page 2 – Ms. Debra Ketchum
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, perroits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note (21 - 211 - 211 - 017) process "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Orall Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
M.B. Egelerisi. MUD
Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Image /page/5/Picture/0 description: The image shows the logo and address of Bausch & Lomb. The address is 1400 North Goodman Street, Rochester, NY 14609. The logo is a stylized black shape above the company name.
Indications for Use Statement
KOGII 57 510(k) Number (if known):
SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Device Name: Lens
Indications for Use:
The SofLens® daily disposable (hilafilcon B) Visibility Tinted Contact Lens is indicated for the daily wear correction of refractive ametropia (myopia, hyperopia and astigmatism) in aphakic and/or not-aphakic persons with nondiseased eyes, that exhibit refractive astigmatism up to 2.00 diopters or less, that does not interfere with visual acuity. The lens may be prescribed in spherical powers ranging from +20.00D to -20.00D.
The lens is to be prescribed for single-use disposable wear, and is to be discarded after each removal.
Prescription Use √ AND/OR Over-The-Counter Use __
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Ode Fute
510(k) Number K061157